| Compound | PT-141 (Bremelanotide) |
|---|---|
| Category | Melanocortin-4 receptor agonist |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Approved medicine |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
PT-141 (Bremelanotide) is catalogued here as a melanocortin-4 receptor agonist and graded at the "Approved medicine" evidence tier. This compound exists as an approved medicine in at least one major jurisdiction. Approval applies to specific, labeled indications and to the regulated product — not to compounded or research-grade copies.
A melanocortin-4 receptor agonist approved by the FDA as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Mechanism of Action
Bremelanotide acts centrally on melanocortin receptors, influencing sexual motivation pathways rather than the peripheral vascular mechanisms of older ED drugs.
Research and Evidence
Registrational trials (RECONNECT program) demonstrated improvement in desire and distress endpoints supporting FDA approval in 2019.
Safety and Side Effects
Labeled effects include transient blood-pressure and heart-rate increases, nausea, and flushing; it is contraindicated with uncontrolled hypertension and in patients at cardiovascular risk.
Frequently Asked Questions
What is the evidence tier of PT-141 (Bremelanotide)?
PT-141 (Bremelanotide) is graded "Approved medicine" on this site. This compound exists as an approved medicine in at least one major jurisdiction. Approval applies to specific, labeled indications and to the regulated product — not to compounded or research-grade copies.
Is PT-141 (Bremelanotide) an approved medicine?
PT-141 (Bremelanotide) exists as an approved medicine in at least one major jurisdiction — but approval covers the regulated product and its labeled indications only. Compounded or research-grade versions of the same molecule are not the approved product.
Where can I read the primary studies for PT-141 (Bremelanotide)?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- DailyMed — Vyleesi (bremelanotide) prescribing information. [source]
Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.